All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Phase III Pivotal REFRESH Study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Faran Shimi Pharmaceutical Company
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration December 15, 2020
Details:
Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Xediton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $11.3 million
Deal Type: Licensing Agreement October 28, 2020
Details:
Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Qilu Pharmaceutical Co., Ltd.
Deal Size: Undisclosed Upfront Cash: $50.0 million
Deal Type: Licensing Agreement October 19, 2020
Details:
Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
First patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical laboratory.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
